| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-03-04 | BAX 826 (rFVIII - recombinant factor VIII - SHP656) | hemophilia A | 1 | Baxalta (USA - IL), now Shire (UK - USA) | Rare diseases - Genetic diseases - Hematological diseases |
| 2016-03-04 | AKN-028 | acute myeloid leukemia (AML) | 1-2 | Akinion Pharmaceuticals (Sweden) | Cancer - Oncology |
| 2016-03-04 | vatelizumab | relapsing remitting multiple sclerosis (RRMS) | 2 | Genzyme (USA - MA), a Sanofi company | Autoimmune diseases - Neurodegenerative diseases |
| 2016-03-04 | SAR3419 (coltuximab ravtansine) | non-Hodgkin's lymphoma (NHL) and other B-cell malignancies | 2 | Immunogen (USA) Sanofi (France) | Cancer - Oncology |
| 2016-03-03 | Keytruda® (pembrolizumab - MK-3475) | hepatocellular carcinoma | 2 | Merck&Co (USA - NJ) | Cancer - Oncology |
| 2016-03-03 | PRX-102 (alpha-galactosidase-A) | Fabry disease | Protalix BioTherapeutics (Israel) | Rare diseases - Genetic diseases | |
| 2016-03-03 | Benlysta® (belimumab) | systemic lupus erythematosus (SLE) | 3 | GSK (UK) | Autoimmune diseases |
| 2016-03-02 | SBC-103 (rhNAGLU enzyme) | mucopolysaccharidosis IIIB (Sanfilippo B syndrome) | 1-2 | Synageva BioPharma (USA - MA), now Alexion Pharmaceuticals (USA - CT) | Rare diseases - Genetic diseases |
| 2016-03-02 | coronary artery disease | Regeneron Pharmaceuticals (USA - NY) Geisinger Health System (USA - PA) | Cardiovascular diseases | ||
| 2016-03-02 | danegaptide | ischemic reperfusion injury | 2 | Zealand Pharma (Denmark) | Cardiovascular diseases |
| 2016-03-02 | cutaneous T-cell lymphoma (CTCL) | Cancer - Oncology | |||
| 2016-03-02 | MRG-106 | cutaneous T-cell lymphoma (CTCL), mycosis fungoides subtype | 1 | Miragen Therapeutics (USA - CO) | Cancer - Oncology - Rare diseases |
| 2016-03-02 | MSB11022, a biosimilar version of Humira® (adalimumab) | moderate to severe chronic plaque psoriasis | 3 | Merck KGaA (Germany) | Autoimmune diseases - Dermatological diseases |
| 2016-03-01 | aramchol | HIV-associated lipodystrophy and nonalcoholic fatty liver disease (NAFLD) | 2 | Galmed Pharmaceuticals (Israel) | Hepatic diseases - Liver diseases |
| 2016-03-01 | MSB0011359C (M7824) | solid tumors | 1 | Merck KGaA (Germany) | Cancer - Oncology |
| 2016-02-29 | MK-8628 (formerly known as OTX015) | advanced nuclear protein in testis (NUT) midline carcinoma (NMC), triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), or castration-resistant prostate cancer (CRPC) | 1 | Merck&Co (USA - NJ) | Cancer - Oncology |
| 2016-02-29 | MK-8628 (formerly known as OTX015) | acute myeloid leukemia (AML) Including AML de Novo and AML secondary to myelodysplastic syndrome (MDS) and in participants with diffuse large B cell lymphoma (DLBCL). | 1 | Merck&Co (USA - NJ) | Cancer - Oncology |
| 2016-02-26 | PM184 | advanced breast cancer, hormone-receptor positive,HER2-negative, locally advanced and/or metastatic breast cancer | 2 | PharmaMar (Spain) | Cancer - Oncology |
| 2016-02-25 | ABX464 | HIV/Aids | 2a | Abivax (France) | Infectious diseases |
| 2016-02-25 | BLZ-100 - chlorotoxin conjugated to indocyanine green dye | head and neck squamous cell carcinoma | preclinical | Blaze Biosciences (USA - WA) | Cancer - Oncology |
